Breaking News
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - ClinicalTrials.gov: Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
January 16, 2018 - FDA grants approval for first drug to treat inherited breast cancer
January 16, 2018 - Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells
January 16, 2018 - Fresh, Frozen Embryos Equal in IVF
January 16, 2018 - Research shows biological clocks could improve brain cancer treatment
January 16, 2018 - Dire view from within accident and emergency wards of England and Wales
January 16, 2018 - Study reveals how devastating mitochondrial diseases strike families without any previous history
January 16, 2018 - Experts look for ways to standardize treatments for pediatric rheumatic diseases
January 16, 2018 - Teens who watch TV shows with ads likely to eat more junk food
January 16, 2018 - Aztec apocalypse found to be Salmonella outbreak
January 16, 2018 - Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber’s Hereditary Optic Neuropathy
January 16, 2018 - Three Ineffective Institutional Approaches to Quality Improvement in Healthcare
January 16, 2018 - New technology accelerates autism diagnosis and treatment
January 16, 2018 - Preterm babies likely to experience delays in auditory brain development, study reveals
January 16, 2018 - Research sheds new light on genetic, environmental factors that promote prostate cancer metastasis
January 16, 2018 - Mitochondrial impairment may actually protect the brain in Parkinson’s disease, study shows
January 15, 2018 - Energy drinks can have adverse health effects on youth, study reveals
January 15, 2018 - 60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug Tafenoquine
January 15, 2018 - Wanted: ‘Breathalyzer’ for Cannabis Use
January 15, 2018 - Surfers more likely to get antibiotic resistant E. coli in their guts
January 15, 2018 - “Baby brain” a real clinical entity finds study
January 15, 2018 - Whole of Britain to be put on a diet plan come March
January 15, 2018 - Neighborhood Deprivation Linked to Heart Failure
January 15, 2018 - Omega-3 and Omega-6 fatty acid intake may affect lupus outcomes
January 15, 2018 - Scientists discover new enzyme that could reduce obesity rates
January 15, 2018 - Evidence suggests two patterns of early symptoms precede and predict later BD risk
January 15, 2018 - Harm minimization approach for smoking cessation with e-cigarettes
January 15, 2018 - Surgery or Antibiotics for Appendicitis? Here’s What Patients Chose
January 15, 2018 - ASH: Frailty Screening Tool Guides Therapy in Elderly
January 15, 2018 - Study shows video games could cut dementia risk in seniors
January 15, 2018 - Common Food Additive Promoting C. diff?
January 15, 2018 - Mild traumatic brain injury causes long-term damage in mice
January 15, 2018 - Circadian clock proteins set the pace of plant growth
January 15, 2018 - Two proteins shown to regenerate brain in Parkinson’s disease
January 15, 2018 - Jotting down tasks may ease falling asleep, study says
January 15, 2018 - Chi-Med Initiates Fruquintinib U.S. Clinical Trials
January 15, 2018 - Cell-Free DNA May Help Pinpoint Breast Ca Survival
January 15, 2018 - What goes on inside a medically supervised injection facility?
January 15, 2018 - Research provides new model to better ascertain HIV mortality rates in Zambia
January 15, 2018 - Genetic analysis can enhance outcomes of depression treatment
January 15, 2018 - Variations in bacterial strains can trigger varying immune responses, study states
January 15, 2018 - TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
January 15, 2018 - HIV Vaccine Shows ‘Positive Signal’ in Small Study
January 15, 2018 - Researchers demonstrate RAS dimers are essential for cancer
January 15, 2018 - Groundbreaking report highlights plan to end bowel cancer
January 15, 2018 - Doc Aspires to Bring ‘Medicine the Musical’ to Off-Broadway
January 15, 2018 - Does an exploding brain network cause chronic pain?
January 15, 2018 - Researchers use novel PET tracer to assess myelin damage in mouse models of MS
January 15, 2018 - Survival strategy of mRNAs during sugar deficiency in the cell
January 15, 2018 - Hormone Therapy May Ease Depression Linked to Menopause
January 15, 2018 - Pain Sensitization Declines After Bariatric Tx in Obese Patients
January 15, 2018 - C7 nerve transfer improves function in spastic arm paralysis
January 15, 2018 - Australian kids are drinking and smoking far less than before
January 15, 2018 - Worsening of anxiety symptoms may be early indicator of Alzheimer’s disease
January 15, 2018 - Early testing for influenza symptoms can limit severe, life-threatening disease
January 15, 2018 - Exposure to estrogen-mimicking compounds may reverse effects of breast cancer treatment
January 15, 2018 - Lipids May Play Key Role in Abdominal Aneurysm
January 15, 2018 - Raw Dough’s a Raw Deal and Could Make You Sick
January 15, 2018 - Thinking about germs makes people concerned about how they look
January 15, 2018 - Pitt scientists develop new guidelines to alleviate EMS personnel fatigue
January 15, 2018 - Discovery suggests new approach for targeting most-wanted molecular culprits in cancer
January 14, 2018 - Rhizen Pharmaceuticals S.A. Receives FDA Orphan-Drug Designation for Tenalisib (RP6530) for Treatment of Peripheral T-Cell Lymphoma (PTCL)
January 14, 2018 - Adding Enzyme to Chemo Combo Improves Outcomes in Pancreatic CA
January 14, 2018 - Research suggests ways to help mentally ill in Ghana’s prayer camps
January 14, 2018 - U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer
January 14, 2018 - Availability of qualified nurses in hospitals affects patient satisfaction
January 14, 2018 - Prostate cancer’s gene-determined ‘immune landscape’ dictates tumor progression
January 14, 2018 - Online CME: Is This Your First Choice?
Proteasome inhibitor treatment can lead to cardiovascular problems in multiple myeloma patients

Proteasome inhibitor treatment can lead to cardiovascular problems in multiple myeloma patients

image_pdfDownload PDFimage_print

The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients. An analysis of past studies shows 18 percent of multiple myeloma patients receiving carfilzomib experience cardiovascular adverse events (CVAE) such as hypertension, heart failure, heart attacks, or arrhythmia. More than eight percent of patients experience high-grade CVAEs that are more severe, which is more than twice as common as with other drugs for treating relapsed myeloma. Researchers published their findings today in JAMA Oncology.

Multiple myeloma (MM) is a bone marrow cancer that affects plasma cells. Normal plasma cells work as part of the immune system, but in MM these cells become cancerous and grow out of control, leading to multiple painful bone tumors, as well as anemia, kidney failure, and recurrent infections. The American Cancer Society estimates there were more than 30,200 new cases of MM in 2017. Standard treatments include chemotherapy and radiation. Survival of these patients has improved with the use of proteasome inhibitors.

Carfilzomib is one of three proteasome inhibitors currently approved for use by the U.S. Food and Drug Administration. Proteasomes are essentially garbage workers that break down and eliminate proteins inside a cell. Diseases that require more protein turnover to survive, like MM, need more proteasomes. The inhibitor drugs block them from doing their job, causing the cells to fill up with protein and die.

“Like any cancer therapy, the concern with this approach is that it may have an effect on an otherwise healthy part of the body – in this case, the heart,” said the study’s lead author Adam J. Waxman, MD, a Hematology Oncology fellow in the Perelman School of Medicine at the University of Pennsylvania.

Brendan M. Weiss, MD, an adjunct professor of Hematology Oncology at Penn, is the study’s senior author. Weiss also works in research and development at Janssen Pharmaceuticals, which does not manufacture or support any of the drugs involved in this analysis.

Researchers gathered data from 24 studies reported from 2007 through 2017, which included information on 2,594 MM patients. They found 18.1 percent of patients who took carfilzomib experienced CVAE, with 8.2 percent of those cases being grade three or higher, meaning they are categorized as severe. For comparison, a similar review of bortezomib, another proteasome inhibitor, found just 3.8 percent of patients experienced CVAE and only 2.3 percent were severe.

The most common CVAEs were hypertension (12.2 percent) and heart failure (4.1 percent). Arrhythmias (2.4 percent) and ischemic events (1.8) – in which there isn’t enough blood flow to the heart leading to the death of heart muscle – were observed less commonly. Researchers also found that higher doses of carfilzomib are associated with higher rates of CVAE, and that carfilzomib was associated with an elevated risk of CVAE compared to control groups who did not receive carfilzomib. “Taken together, these findings argue that carfilzomib is responsible for an elevated risk, and anyone who is treating patients with this drug needs to be aware that this is a common event,” Waxman said.

Researchers say these findings are particularly important since there are already overlapping risk factors for both MM and cardiovascular disease, such as older age and obesity. Previous studies have shown nearly two-thirds of MM patients had cardiovascular disease at baseline, and 70 percent experienced cardiovascular events within six years.

“Clinicians should be paying attention to who may be at highest risk for these events so they can tailor their therapy accordingly,” Waxman said.

Researchers also called for further clinical trials to specifically evaluate this connection, arguing that it may be underrepresented by current data.

“If you’re not specifically looking for this, you might report it differently,” Waxman said.

Source:

http://www.uphs.upenn.edu/

Tagged with:

About author

Related Articles